Association between eupatilin and reduction in small bowel bleeding in aspirin users and aspirin plus acid suppressant users
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Capsule endoscopy (CE) has shown that low-dose aspirin occasionally causes small bowel (SB) bleeding. We herein evaluated the protective effects of mucoprotective agents (MPAs) on SB bleeding in aspirin users using the nationwide database of claims data from the National Health Insurance Service (NHIS). Methods: As CE is an insured procedure, we constructed an aspirin-SB cohort using NHIS claims data, with a maximum follow- up period of 24 months. Patients with anemia, melena, or hematochezia that occurred within 4 weeks before and after performing CE were suspected to have SB bleeding. A Cox proportional hazards regression model was used to determine the risk factors for SB bleeding. Subgroup analyses were conducted among patients who used acid suppressants, such as proton pump inhibitors (PPIs) and histamine-2 receptor antagonists. Results: A total of 15,542 aspirin users were included. Anticoagulant use (hazard ratio [HR], 3.22), high Charlson comorbidity index score (≥ 2) (HR, 3.54), and PPI use (HR, 2.85) were significantly associated with SB bleeding, whereas eupatilin use (HR, 0.35) was a preventive factor. SB bleeding occurred more frequently in concurrent users of acid suppressants than in nonusers (1.3% vs. 0.5%). Subgroup analysis revealed that eupatilin significantly reduced the risk of SB bleeding in aspirin users with concurrent use of acid suppressants (HR, 0.23 vs. 2.55). Conclusions: Eupatilin was associated with a reduced risk of SB bleeding in both aspirin users and those with concomitant use of acid suppressants. Eupatilin use should be considered for aspirin users, especially for those concomitantly taking acid suppressants.
Abstract
Background/Aims: Capsule endoscopy (CE) has shown that low-dose aspirin occasionally causes small bowel (SB) bleeding. We herein evaluated the protective effects of mucoprotective agents (MPAs) on SB bleeding in aspirin users using the nationwide database of claims data from the National Health Insurance Service (NHIS). Methods: As CE is an insured procedure, we constructed an aspirin-SB cohort using NHIS claims data, with a maximum follow- up period of 24 months. Patients with anemia, melena, or hematochezia that occurred within 4 weeks before and after performing CE were suspected to have SB bleeding. A Cox proportional hazards regression model was used to determine the risk factors for SB bleeding. Subgroup analyses were conducted among patients who used acid suppressants, such as proton pump inhibitors (PPIs) and histamine-2 receptor antagonists. Results: A total of 15,542 aspirin users were included. Anticoagulant use (hazard ratio [HR], 3.22), high Charlson comorbidity index score (≥ 2) (HR, 3.54), and PPI use (HR, 2.85) were significantly associated with SB bleeding, whereas eupatilin use (HR, 0.35) was a preventive factor. SB bleeding occurred more frequently in concurrent users of acid suppressants than in nonusers (1.3% vs. 0.5%). Subgroup analysis revealed that eupatilin significantly reduced the risk of SB bleeding in aspirin users with concurrent use of acid suppressants (HR, 0.23 vs. 2.55). Conclusions: Eupatilin was associated with a reduced risk of SB bleeding in both aspirin users and those with concomitant use of acid suppressants. Eupatilin use should be considered for aspirin users, especially for those concomitantly taking acid suppressants.
참고문헌 (22)
- Luepker RV, "Population trends in aspirin use for cardiovascular disease prevention 1980-2009 : the Minnesota Heart Survey", J Am Heart Assoc, 4, pp.e002320~ (2015)
- Brett AS, "Should patients take aspirin for primary cardiovascular prevention? : updated recommendations from the US preventive services task force", JAMA, 327, pp.1552~1554 (2022)
- Gurwitz JH, "Incidence and preventability of adverse drug events among older persons in the ambulatory setting", JAMA, 289, pp.1107~1116 (2003)
- 임윤정, "Advent of Novel Phosphatidylcholine-Associated Nonsteroidal Anti-Inflammatory Drugs with Improved Gastrointestinal Safety", Gut and Liver, 7(1), pp.7~15 (2013), 거트앤리버 소화기연관학회협의회
- 심기남, "Long-Term Outcomes of NSAID-Induced Small Intestinal Injury Assessed by Capsule Endoscopy in Korea: A Nationwide Multicenter Retrospective Study", Gut and Liver, 9(6), pp.727~733 (2015), 거트앤리버 소화기연관학회협의회
- 임윤정, "Indications for Detection, Completion, and Retention Rates of Small Bowel Capsule Endoscopy Based on the 10-Year Data from the Korean Capsule Endoscopy Registry", Clinical Endoscopy, 48(5), pp.399~404 (2015), 대한소화기내시경학회
- Su Hwan Kim, "Changes in performance of small bowel capsule endoscopy based on nationwide data from a Korean Capsule Endoscopy Registry", The Korean Journal of Internal Medicine, 35(4), pp.889~896 (2020), 대한내과학회[DOI]
- Song JH, "The etiology of potential small-bowel bleeding depending on patient's age and gender", United European Gastroenterol J, 6, pp.1169~1178 (2018)
- Lim DH, "Non-steroidal anti-inflammatory drug-induced enteropathy as a major risk factor for small bowel bleeding : a retrospective study", BMC Gastroenterol, 20, pp.178~ (2020)
- Wallace JL, "Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis", Gastroenterology, 141, pp.1314~1322 (2011)
- Edogawa S, "Current topics of strategy of NSAID-induced small intestinal lesions", Digestion, 92, pp.99~107 (2015)
- Kyaw MH, "Misoprostol heals small bowel ulcers in aspirin users with small bowel bleeding", Gastroenterology, 155, pp.1090~1097 (2018)
- Niwa Y, "Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects : a prospective, randomized, double-blinded, placebo-controlled, cross-over study", J Gastroenterol, 43, pp.270~276 (2008)
- Raju GS, "American Gastroenterological Association(AGA)Institute technical review on obscure gastrointestinal bleeding", Gastroenterology, 133, pp.1697~1717 (2007)
- Pennazio M, "Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders : European Society of Gastrointestinal Endoscopy(ESGE)clinical guideline", Endoscopy, 47, pp.352~376 (2015)
- Endo H, "Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users : data from a prospective multicenter capsule endoscopy registry", Gastrointest Endosc, 80, pp.826~834 (2014)
- Kim TJ, "Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users", Sci Rep, 9, pp.11696~ (2019)
- Lim YJ, "In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine", Digestion, 86, pp.171~177 (2012)
- Lué A, "Protons pump inhibitor treatment and lower gastrointestinal bleeding : balancing risks and benefits", World J Gastroenterol, 22, pp.10477~10481 (2016)
- Kurokawa S, "A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and", or non-steroidal anti-inflammatory drug induced small bowel injury, 2014, pp.49, 239~244
- Watari I, "Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy : a pilot randomized controlled study", BMC Gastroenterol, 13, pp.108~ (2013)
- 이강녕, "Prevention of NSAID-Associated Gastroduodenal Injury in Healthy Volunteers-A Randomized, Double-Blind, Multicenter Study Comparing DA-9601 with Misoprostol", Journal of Korean Medical Science, 26(8), pp.1074~1080 (2011), 대한의학회